Literature DB >> 11600691

Cardiac troponin T mutations: correlation between the type of mutation and the nature of myofilament dysfunction in transgenic mice.

D E Montgomery1, J C Tardiff, M Chandra.   

Abstract

1. The heterogenic nature of familial hypertrophic cardiomyopathy (FHC) in humans suggests a link between the type of mutation and the nature of patho-physiological alterations in cardiac myocytes. Exactly how FHC-associated mutations in cardiac troponin T (cTnT) lead to impaired cardiac function is unclear. 2. We measured steady-state isometric force and ATPase activity in detergent-skinned cardiac fibre bundles from three transgenic (TG) mouse hearts in which 50, 92 and 6 % of the native cTnT was replaced by the wild type (WT) cTnT, R92Q mutant cTnT (R92Q) and the C-terminal deletion mutant of cTnT (cTnT(DEL)), respectively. 3. Normalized pCa-tension relationships of R92Q and cTnT(DEL) fibres demonstrated a significant increase in sensitivity to Ca2+ at short (2.0 microm) and long (2.3 microm) sarcomere lengths (SL). At short SL, the pCa50 values, representing the midpoint of the pCa-tension relationship, were 5.69 +/- 0.01, 5.96 +/- 0.01 and 5.81 +/- 0.01 for WT, R92Q and cTnT(DEL) fibres, respectively. At long SL, the pCa50 values were 5.81 +/- 0.01, 6.08 +/- 0.01 and 5.95 +/- 0.01 for WT, R92Q and cTnT(DEL) fibres, respectively. 4. The difference in pCa required for half-maximal activation (DeltapCa50) at short and long SL was 0.12 +/- 0.01 for the R92Q (92 %) TG fibres, which is significantly less than the previously reported DeltapCa50 value of 0.29 +/- 0.02 for R92Q (67 %) TG fibres. 5. At short SL, Ca2+-activated maximal tension in both R92Q and cTnT(DEL) fibres decreased significantly (24 and 21 %, respectively; P < 0.005), with no corresponding decrease in Ca2+-activated maximal ATPase activity. Therefore, at short SL, the tension cost in R92Q and cTnT(DEL) fibres increased by 35 and 29 %, respectively (P < 0.001). 6. The fibre bundles reconstituted with the recombinant mutant cTnT(DEL) protein developed only 37 % of the Ca2+-activated maximal force developed by recombinant WT cTnT reconstituted fibre bundles, with no apparent changes in Ca2+ sensitivity. 7. Our data indicate that an important mutation-linked effect on cardiac function is the result of an inefficient use of ATP at the myofilament level. Furthermore, the extent of the mutation-induced dysfunction depends not only on the nature of the mutation, but also on the concentration of the mutant protein in the sarcomere.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11600691      PMCID: PMC2278862          DOI: 10.1111/j.1469-7793.2001.0583c.xd

Source DB:  PubMed          Journal:  J Physiol        ISSN: 0022-3751            Impact factor:   5.182


  32 in total

1.  Ca(2+) activation of myofilaments from transgenic mouse hearts expressing R92Q mutant cardiac troponin T.

Authors:  M Chandra; V L Rundell; J C Tardiff; L A Leinwand; P P De Tombe; R J Solaro
Journal:  Am J Physiol Heart Circ Physiol       Date:  2001-02       Impact factor: 4.733

2.  Regulation of force and unloaded sliding speed in single thin filaments: effects of regulatory proteins and calcium.

Authors:  E Homsher; D M Lee; C Morris; D Pavlov; L S Tobacman
Journal:  J Physiol       Date:  2000-04-01       Impact factor: 5.182

Review 3.  Hypertrophic cardiomyopathy. Interrelations of clinical manifestations, pathophysiology, and therapy (2).

Authors:  B J Maron; R O Bonow; R O Cannon; M B Leon; S E Epstein
Journal:  N Engl J Med       Date:  1987-04-02       Impact factor: 91.245

4.  Use of chlorotetracycline fluorescence to demonstrate Ca2+-induced release of Ca2+ from the sarcoplasmic reticulum of skinned cardiac cells.

Authors:  A Fabiato; F Fabiato
Journal:  Nature       Date:  1979-09-13       Impact factor: 49.962

5.  Phosphorylation of troponin I by protein kinase A accelerates relaxation and crossbridge cycle kinetics in mouse ventricular muscle.

Authors:  J C Kentish; D T McCloskey; J Layland; S Palmer; J M Leiden; A F Martin; R J Solaro
Journal:  Circ Res       Date:  2001-05-25       Impact factor: 17.367

6.  Altered regulatory function of two familial hypertrophic cardiomyopathy troponin T mutants.

Authors:  P Mukherjea; L Tong; J G Seidman; C E Seidman; S E Hitchcock-DeGregori
Journal:  Biochemistry       Date:  1999-10-05       Impact factor: 3.162

7.  Transgenic incorporation of skeletal TnT into cardiac myofilaments blunts PKC-mediated depression of force.

Authors:  D E Montgomery; M Chandra; Q Huang; J Jin; R J Solaro
Journal:  Am J Physiol Heart Circ Physiol       Date:  2001-03       Impact factor: 4.733

8.  Inhibition of the activation and troponin calcium binding of dog cardiac myofibrils by acidic pH.

Authors:  E M Blanchard; R J Solaro
Journal:  Circ Res       Date:  1984-09       Impact factor: 17.367

9.  Phosphorylation of C-protein, troponin I and phospholamban in isolated rabbit hearts.

Authors:  J L Garvey; E G Kranias; R J Solaro
Journal:  Biochem J       Date:  1988-02-01       Impact factor: 3.857

10.  Influence of temperature upon contractile activation and isometric force production in mechanically skinned muscle fibers of the frog.

Authors:  R E Godt; B D Lindley
Journal:  J Gen Physiol       Date:  1982-08       Impact factor: 4.086

View more
  39 in total

1.  The C-terminus of troponin T is essential for maintaining the inactive state of regulated actin.

Authors:  Andrew J Franklin; Tamatha Baxley; Tomoyoshi Kobayashi; Joseph M Chalovich
Journal:  Biophys J       Date:  2012-06-05       Impact factor: 4.033

Review 2.  Hypertrophic cardiomyopathy: from genetics to treatment.

Authors:  Ali J Marian
Journal:  Eur J Clin Invest       Date:  2010-04       Impact factor: 4.686

3.  Changes in the chemical and dynamic properties of cardiac troponin T cause discrete cardiomyopathies in transgenic mice.

Authors:  Briar R Ertz-Berger; Huamei He; Candice Dowell; Stephen M Factor; Todd E Haim; Sara Nunez; Steven D Schwartz; Joanne S Ingwall; Jil C Tardiff
Journal:  Proc Natl Acad Sci U S A       Date:  2005-12-02       Impact factor: 11.205

4.  Interplay between the overlapping ends of tropomyosin and the N terminus of cardiac troponin T affects tropomyosin states on actin.

Authors:  Ranganath Mamidi; John Jeshurun Michael; Mariappan Muthuchamy; Murali Chandra
Journal:  FASEB J       Date:  2013-06-07       Impact factor: 5.191

5.  Instability in the central region of tropomyosin modulates the function of its overlapping ends.

Authors:  Ranganath Mamidi; Mariappan Muthuchamy; Murali Chandra
Journal:  Biophys J       Date:  2013-11-05       Impact factor: 4.033

6.  L71F mutation in rat cardiac troponin T augments crossbridge recruitment and detachment dynamics against α-myosin heavy chain, but not against β-myosin heavy chain.

Authors:  Sherif M Reda; Sampath K Gollapudi; Murali Chandra
Journal:  J Muscle Res Cell Motil       Date:  2016-12-14       Impact factor: 2.698

Review 7.  Research priorities in sarcomeric cardiomyopathies.

Authors:  Jolanda van der Velden; Carolyn Y Ho; Jil C Tardiff; Iacopo Olivotto; Bjorn C Knollmann; Lucie Carrier
Journal:  Cardiovasc Res       Date:  2015-01-28       Impact factor: 10.787

8.  The role of Akt/GSK-3beta signaling in familial hypertrophic cardiomyopathy.

Authors:  Stephen W Luckey; Lori A Walker; Tyson Smyth; Jason Mansoori; Antke Messmer-Kratzsch; Anthony Rosenzweig; Eric N Olson; Leslie A Leinwand
Journal:  J Mol Cell Cardiol       Date:  2009-02-21       Impact factor: 5.000

9.  Developmental changes in contractility and sarcomeric proteins from the early embryonic to the adult stage in the mouse heart.

Authors:  Sharon Siedner; Martina Krüger; Mechthild Schroeter; Doris Metzler; Wilhelm Roell; Bernd K Fleischmann; Juergen Hescheler; Gabriele Pfitzer; Robert Stehle
Journal:  J Physiol       Date:  2003-03-14       Impact factor: 5.182

10.  Decreased contractility due to energy deprivation in a transgenic rat model of hypertrophic cardiomyopathy.

Authors:  Mark Luedde; Ulrich Flögel; Maike Knorr; Christina Grundt; Hans-Joerg Hippe; Benedikt Brors; Derk Frank; Uta Haselmann; Claude Antony; Mirko Voelkers; Juergen Schrader; Patrick Most; Bjoern Lemmer; Hugo A Katus; Norbert Frey
Journal:  J Mol Med (Berl)       Date:  2009-02-03       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.